← SynDRA
TEMOZOLOMIDE
SynDRA canonical compound SYN0001973 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | MGMT |
|---|
| Mechanism of action | DNA alkylating agent |
|---|
| Indication | astrocytoma | glioblastoma |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCB1
- HTR7
- NPY1R
- MLNR
- MC4R
- MC3R
- MBNL1
- MAOA
- KDR
- KCNH2
- HTR6
- NR1I2
- HTR3A
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- NPY2R
- NR3C1
- GIPR
- PTGS2
- TACR1
- SLC6A4
- SLC6A3
- SLC6A2
- SLC47A2
- SLC47A1
- SLC29A1
- SAMHD1
- PPARG
- NTSR1
- POLK
- PGR
- PDE4D
- PDE3A
- PABPC1
- OPRM1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Alkylating Activity
- Alkylating Drug
- Alkylating Agents
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Noxae
ATC classes
Cross-references
Synonyms
- TEMODAR
- Temodar
- temomedac
- SCH 52365
- methazolastone
- temodal
- temozolamide
- Temozolomida
- Methazolastone
- Mk-7365
- CCRG-81045
- M&B-39831
- M-39831
- NSC-362856
- SCH-52365
- Temodal
- Temomedac
- Temozolomide accord
- Temozolomide hexal
- Temozolomide sandoz
- Temozolomide sun
- Temozolomide teva
- Temozolamide
- Temozolodida
- Temozolomidum
- Essex brand of temozolomide
- Scheringbrand of temozolomide
- Temozolodida [Spanish]
- Temozolomidum [Latin]
- M B 39831
- MB 39831
- Sch-52365
- M & B 39831
- Schering-Plough brand of temozolomide
- TMZ-Bioshuttle
- Temodal (TN)
- Temodar (TN)
Reported adverse events
- Myelosuppression
- Diabetes insipidus
- Fatigue
- Infection
- Rash
- Toxic epidermal necrolysis
- Stevens-Johnson syndrome
- Ataxia
- Erythema
- Stomatitis
- Opportunistic infection
- Erythema multiforme
Look up TEMOZOLOMIDE in the interactive SynDRA portal →